Table 1.
Characteristics of the Study Patients
| Characteristics | Number of Patients (%)a |
p Valueb | |
|---|---|---|---|
| Chemo-Cohort (n = 71) | ICI Combo-Cohort (n = 64) | ||
| Median age (range), yc | 73 (35–84) | 72 (34–83) | 0.384 |
| Sex | |||
| Male | 55 (77.5) | 53 (82.8) | 0.520 |
| Female | 16 (22.5) | 11 (17.2) | |
| ECOG performance status | |||
| 0–1 | 54 (76.1) | 55 (85.9) | 0.293 |
| 2 | 12 (16.9) | 5 (7.8) | |
| 3–4 | 5 (7.0) | 4 (6.3) | |
| Smoking statusd | |||
| Current or former | 68 (95.8) | 63 (98.4) | 0.687 |
| Never | 2 (2.8) | 1 (1.6) | |
| Unknown | 1 (1.4) | 0 (0) | |
| Stage | |||
| Limited | 8 (11.3) | 4 (6.3) | 0.374 |
| Extensive | 63 (88.7) | 60 (93.8) | |
| Metastasis at baseline | |||
| CNS | 17 (23.9) | 20 (31.2) | 0.440 |
| Intrathoracic only | 9 (12.7) | 9 (14.1) | 1.00 |
| Extrathoracic | 54 (76.1) | 52 (81.3) | 0.532 |
| Histologic diagnosis | |||
| Small cell | 66 (93.0) | 61 (95.3) | 0.721 |
| Combined | 5 (7.0) | 3 (4.7) | |
| Treatment | |||
| Surgery | 9 (12.7) | 4 (6.3) | 0.252 |
| Radiotherapy | 4 (5.6) | 6 (9.4) | 0.517 |
| PD-L1 TPS (22C3) | |||
| ≥1% | 3 (4.2) | 3 (4.7) | 1.00 |
| <1% | 68 (95.8) | 61 (95.3) | |
| PD-L1 CPS (22C3) | |||
| ≥1% | 18 (25.4) | 9 (14.1) | 0.132 |
| <1% | 53 (74.6) | 55 (85.9) | |
CNS, central nervous system; CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.
a
Percentages may not add up to 100 because of rounding.
b
p Values were determined with the Wilcoxon ranked sum test or Fisher’s exact test as appropriate.
c
At the start of treatment.
d
Current smokers, individuals who had smoked a cigarette within the previous year; former smokers, those who had smoked more than or equal to 100 cigarettes but had quit more than 1 year before diagnosis; never smokers, those who had smoked less than 100 cigarettes.